首页> 美国卫生研究院文献>other >Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features Treatments and Prognosis
【2h】

Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features Treatments and Prognosis

机译:Xp11.2易位/ TFE3基因融合相关的肾细胞癌:临床特征治疗和预后。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization at our center, were retrospectively reviewed. The 34 patients included 21 females and 13 males aged 3 to 64 years (median age: 27 years). Four patients were children or adolescents (<18 years of age), and 26 patients were young or middle-aged adults (18–45 years). Radical nephrectomy was performed on 25 patients. Laparoscopic nephron-sparing surgery was performed on 9 patients who presented with an isolated mass with a small diameter (<7 cm) and well-defined boundary on computed tomography imaging. Postoperative staging showed that 25 cases (73.53%) were at stage I/II, while 9 cases (26.47%) were at stage III/IV. All stage I/II patients received a favorable prognosis with a three-year overall survival rate of 100%, including the patients who underwent laparoscopic nephron-sparing surgery. With the exception of 2 children, the other 7 stage III/IV patients died or developed recurrence with a median follow-up of 29 months. On univariate analysis, maximum diameter, adjuvant treatment, TNM stage, lymph node metastasis, inferior vena cava tumor thrombosis and tumor boundary were identified as statistically significant factors impacting survival (P<0.05). Multivariate analysis indicated that TNM stage and inferior vena cava tumor thrombosis were independent prognostic factors (P<0.05). In conclusion, Xp11.2 tRCC is a rare subtype of renal cell carcinoma that mainly occurs in young females. Nephron-sparing surgery was confirmed effective preliminarily in the treatment of small Xp11.2 tRCCs with clear rims. Advanced TNM stage and inferior vena cava tumor thrombosis were associated with poor prognosis.
机译:目的探讨免疫组织化学法诊断Xp11.2易位/ TFE3基因融合(Xp11.2 tRCC)相关的肾细胞癌的临床特点,治疗及预后,并分析34例Xp11.2 tRCC的流行病学特点及治疗结果。回顾性地回顾了我们中心的TFE3染色和荧光原位杂交。 34例患者包括3到64岁(中位年龄:27岁)的21位女性和13位男性。四名患者为儿童或青少年(<18岁),26例为年轻人或中年成年人(18-45岁)。 25例患者进行了根治性肾切除术。腹腔镜肾保留手术是对9例患者进行的,这些患者表现为孤立的肿块,直径较小(<7 cm),并且在计算机断层扫描成像中边界清晰。术后分期显示I / II期25例(73.53%),III / IV期9例(26.47%)。所有I / II期患者(包括接受腹腔镜肾保留肾手术的患者)预后良好,三年总生存率为100%。除2名儿童外,其他7名III / IV期患者死亡或复发,平均随访29个月。在单因素分析中,最大直径,辅助治疗,TNM分期,淋巴结转移,下腔静脉肿瘤血栓形成和肿瘤边界被确定为影响生存的统计学显着因素(P <0.05)。多因素分析表明,TNM分期和下腔静脉肿瘤血栓形成是独立的预后因素(P <0.05)。总之,Xp11.2 tRCC是一种罕见的肾细胞癌亚型,主要发生在年轻女性中。初步证实,保留肾单位的手术可有效治疗边缘清晰的小型Xp11.2 tRCC。晚期TNM分期和下腔静脉肿瘤血栓形成与预后不良有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号